Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma

Tom CornelisDivision of Nephrology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The NetherlandsCorrespondence[email protected]

Erik A.M. BeckersDivision of Hematology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

Ann L.C. DriessenDepartment of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands

Frank M. van der SandeDivision of Nephrology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

Ger H. KoekDivision of Gastro-Enterology/Hepatology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

References

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, . A phase 2 study of bortezomib in relapsed refractory myeloma. N Engl J Med 2003; 348:2609–2617.
PubMed Web of Science ®Google Scholar
Rosiñol L, Montoto S, Cibeira MT, Bladé J. Bortezomib-induced severe hepatitis in multiple myeloma. Arch Intern Med 2005; 165: 464–465.
PubMed Web of Science ®Google Scholar
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239–245.
PubMed Web of Science ®Google Scholar
Edwards IR, Aronson JK. Adverse drug reactions. Lancet 2000; 356: 1255–1259.
PubMed Web of Science ®Google Scholar
Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, . Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118:4519–4529.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date